The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children

Vaccine. 2007 Jan 2;25(1):14-8. doi: 10.1016/j.vaccine.2006.07.020. Epub 2006 Aug 1.

Abstract

Objectives: Bacille Calmette-Guerin (BCG), a live attenuated Mycobacterium bovis vaccine, poses a risk to human immunodeficiency virus (HIV)-infected children; this risk has not been well quantified. We estimate the risk of disseminated BCG disease in HIV-infected children in a setting highly endemic for tuberculosis and HIV.

Design and methods: We conducted a prospective hospital-based surveillance study in the Western Cape Province, South Africa. Clinical and laboratory-confirmed cases of disseminated BCG disease in children<1 year of age from January 2002 to December 2004 at a referral hospital were used as numerator data. Denominator data for calculations of disseminated BCG risk were obtained through estimating the total number of HIV-infected infants receiving BCG based on the known vaccination coverage in the study setting, combined with population data on the total number of children<1 year of age, the known HIV prevalence amongst women attending public antenatal care facilities and different scenarios (5-15%) for the rate of vertical HIV transmission.

Results: Nine cases of disseminated BCG disease were identified over the study period, seven of these were in HIV-infected infants. The estimated risk for HIV-infected infants to develop disseminated BCG disease, given a 95% BCG coverage and an HIV prevalence of 12.4-15.4% amongst women, were as follows for different scenarios of vertical HIV transmission: 329-417/100,000 vaccinees (assuming 5% vertical HIV transmission), 164-208/100,000 vaccinees (assuming 10% vertical HIV transmission) and 110-139/100,000 vaccinees (assuming 15% vertical HIV transmission).

Conclusions: The risk of disseminated BCG disease is increased several hundred fold in HIV-infected infants compared to the documented risk in HIV-uninfected infants. Data on the protective effect of BCG in HIV-exposed and infected children is lacking. Population- and hospital-based surveillance is vitally important to more accurately estimate the safety and benefits of BCG in HIV-exposed and infected infants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / epidemiology*
  • AIDS-Related Opportunistic Infections / microbiology
  • Adolescent
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / adverse effects*
  • Child
  • Child, Preschool
  • Female
  • HIV Infections / complications*
  • HIV Infections / epidemiology
  • HIV Infections / immunology
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical
  • Mycobacterium bovis / immunology
  • Mycobacterium bovis / pathogenicity*
  • Risk Factors
  • South Africa / epidemiology
  • Tuberculosis / complications
  • Tuberculosis / epidemiology*
  • Tuberculosis / microbiology
  • Tuberculosis / prevention & control
  • Vaccination / statistics & numerical data

Substances

  • BCG Vaccine